Business context and reporting period
Elanco Animal Health Incorporated filed this Form 10-K for the fiscal year ended December 31, 2018; it was signed February 20, 2019. The filing also presents unaudited fourth-quarter results. Elanco develops, manufactures and sells animal health products for food and companion animals in more than 90 countries. It reported one operating segment. The 2018 statements combine pre-separation results with post-separation consolidated results and may not represent standalone historical costs.
Elanco completed its IPO and separation from Eli Lilly on September 24, 2018. It issued 72.3 million shares, raising approximately $1.66 billion net; Lilly retained 80.2% ownership at year-end. Lilly’s proposed exchange offer for its Elanco shares was pending.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $3,066.8 million | $2,889.0 million |
| Cost of sales | $1,573.8 million | $1,493.9 million |
| Net income (loss) | $86.5 million | $(310.7) million |
| Operating cash flow | $487.3 million | $173.8 million |
| Capital expenditures | $134.5 million | $98.6 million |
| Cash and cash equivalents at year-end | $474.8 million | $323.4 million |
Revenue rose 6% year over year, from 3% higher realized prices and 3% higher volume. Cost of sales was 51% of revenue versus 52% in 2017. Net margin was approximately 3% (reported); Elanco moved from a loss to profit as special charges declined substantially. Research and development expense was $246.6 million, down 2%; marketing, selling and administrative expense was $735.2 million, down 6%. Asset impairment, restructuring and other special charges were $128.8 million, versus $375.1 million.
Revenue by category: Companion Animal Disease Prevention $804.6 million, up 22%; Companion Animal Therapeutics $283.1 million, up 9%; Food Animal Future Protein & Health $711.2 million, up 10%; Food Animal Ruminants & Swine $1,174.0 million, essentially flat; and Strategic Exits $93.9 million, down 35%. Food animal products represented about 61% of revenue and companion animal products about 35%.
Fourth-quarter 2018 revenue was $799.3 million, versus $754.3 million in Q4 2017. Q4 net income was $16.4 million, compared with a net loss of $161.5 million a year earlier. Q4 2018 included $46.0 million of impairment, restructuring and other special charges; Q4 2017 included $185.8 million.
At December 31, 2018, total assets were $8.96 billion and total equity $5.20 billion. Current assets were $2.50 billion and current liabilities $970.7 million. Cash included $202.7 million of restricted cash reserved for the remaining payment to Lilly; a related payable to Lilly was recorded. Operating cash flow increased $313.5 million, although working capital—especially receivables and inventory—used cash.
Debt had been established in connection with the separation: $2.0 billion of senior notes and a $500 million term loan. Year-end debt carrying value was $2.472 billion, including current portion; the term loan rate was 3.77% at year-end. A $750 million revolving facility was undrawn. Elanco said it complied with debt covenants. It estimated annual interest expense of approximately $110 million, versus $29.6 million recognized in 2018 because borrowing began during the year.
Changes, outlook, commentary and risks
- Growth was led by disease prevention products, including Credelio and Interceptor Plus, and by poultry and aquaculture products. Ruminants and Swine remained pressured by ractopamine competition and other market headwinds. Shared-class antibiotic revenue declined 2% in 2018 excluding foreign exchange; it was 12% of total revenue. Animal-only antibiotics and ionophores were 25% of revenue.
- Elanco recorded $37.6 million of additional Galliprant contingent-consideration expense, primarily reflecting higher projected cash flows. It also recorded $38.6 million of inventory write-offs, primarily related to suspension of Imrestor activities. Goodwill was $3.0 billion and other intangibles $2.5 billion; no goodwill impairment was recorded in 2018.
- Management expected cash on hand, operating cash flow and financing arrangements to meet needs for at least the next 12 months. It expected 2019 capital expenditures of approximately $179 million. Elanco stated an intent to pay a quarterly dividend of about $0.06 per share after Lilly no longer owned shares, subject to board discretion; this was not a firm commitment. No formal revenue or earnings guidance is provided in the filing text.
- Management estimated separation-related process and systems costs of $240–$290 million in aggregate, partly capitalized and partly expensed. The company anticipated further standalone costs and continued transition-service reliance on Lilly. Its manufacturing restructuring was expected to be substantially complete by December 2019.
- Key risks include competition and generic substitution, antibiotic-use regulation and changing consumer preferences, reliance on leading products (the top five represented about 31% of 2018 revenue), customer and distributor concentration, product safety and supply interruptions, R&D and regulatory uncertainty, foreign exchange, and execution of the separation. Approximately 72% of revenue came from products without patent protection.
- Other exposures include substantial indebtedness, underfunded pension plans, environmental remediation obligations and exchange-offer tax risk. Management considered the likelihood of material impact from ordinary-course litigation remote, but noted adverse outcomes could be material. A Swiss franc net investment hedge may create significant settlement exposure in 2023.
- The auditor issued an unqualified opinion on the financial statements. The 10-K did not include management’s internal-control assessment or auditor attestation under the newly public company transition period; management concluded disclosure controls were effective.
Most important facts for investors to verify
- Whether 2018 profitability and higher operating cash flow persist after full-year interest costs, separation expenses and working-capital demands.
- Debt repayment capacity, future interest expense, covenant headroom and the intended dividend’s timing and affordability.
- Progress and commercial returns from new products, particularly whether companion-animal growth offsets declines in legacy products and generic competition.
- Exposure to antibiotic restrictions, ractopamine market access, product concentration and the largest distributor, which accounted for about 12% of 2018 revenue.
- Actual standalone costs after Lilly transition services end, completion and cost of restructuring, and the outcome and tax consequences of Lilly’s proposed exchange offer.
- Assumptions supporting goodwill and intangible valuations, pension funding, contingent Galliprant payments, and the Swiss franc hedge’s potential 2023 settlement impact.